D'Agostino H B, vanSonnenberg E, Sanchez R B, Goodacre B W, Villaveiran R G, Lyche K
Department of Radiology, University of California, San Diego 92103-8756.
Radiology. 1993 Jun;187(3):685-8. doi: 10.1148/radiology.187.3.8497614.
In an attempt to decrease catheter drainage of pancreatic pseudocysts, a combined regimen of percutaneous drainage and administration of octreotide acetate was used in eight symptomatic patients. Indications for the combined therapy were pseudocyst recurrence (four patients), pancreatic fistula from percutaneous drainage (two patients), or elective treatment to restrict pancreatic drainage. Octreotide acetate was administered subcutaneously in doses of 50-1,000 micrograms three times a day. The drug was well tolerated and produced only limited adverse effects in four patients: pain at the injection site, hypoglycemia, diarrhea, headaches, and lower-extremity edema (more than one adverse effect was experienced by each patient). The combined use of percutaneous drainage and administration of octreotide was effective in seven patients and failed in one patient who had distal pancreatic duct occlusion. In five patients, catheter drainage decreased to no measurable amount by a mean of 13.8 days. These results suggest octreotide is effective in decreasing the output from pancreatic pseudocysts drained percutaneously.
为了减少胰腺假性囊肿的导管引流，对8例有症状的患者采用了经皮引流联合醋酸奥曲肽给药的治疗方案。联合治疗的指征为假性囊肿复发（4例）、经皮引流导致的胰瘘（2例）或为限制胰腺引流而进行的选择性治疗。醋酸奥曲肽皮下给药，剂量为50 - 1000微克，每日3次。该药物耐受性良好，仅4例患者出现有限的不良反应：注射部位疼痛、低血糖、腹泻、头痛和下肢水肿（每位患者经历一种以上不良反应）。经皮引流联合奥曲肽给药对7例患者有效，1例远端胰管闭塞的患者治疗失败。5例患者的导管引流量平均在13.8天减少至无法测量。这些结果表明奥曲肽在减少经皮引流的胰腺假性囊肿的引流量方面是有效的。
